

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | |
|--|---|---|
| 1. Name and Address of Reporting Person* <u>Jones James</u> <hr/> (Last) (First) (Middle) 2525 WEST END AVENUE SUITE 950 <hr/> (Street) NASHVILLE TN 37203 <hr/> (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol <u>CUMBERLAND PHARMACEUTICALS INC [CPIX]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below) |
| | 3. Date of Earliest Transaction (Month/Day/Year) 10/01/2021 | |
| | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|--------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 10/01/2021 | | P | | 42 ⁽¹⁾ | A | \$2.69 | 17,220 | D | |
| Common Stock | 10/04/2021 | | P | | 42 ⁽¹⁾ | A | \$2.87 | 17,262 | D | |
| Common Stock | 10/05/2021 | | P | | 42 ⁽¹⁾ | A | \$2.82 | 17,304 | D | |
| Common Stock | 10/06/2021 | | P | | 42 ⁽¹⁾ | A | \$2.76 | 17,346 | D | |
| Common Stock | 10/07/2021 | | P | | 42 ⁽¹⁾ | A | \$2.76 | 17,388 | D | |
| Common Stock | 10/08/2021 | | P | | 42 ⁽¹⁾ | A | \$2.84 | 17,430 | D | |
| Common Stock | 10/11/2021 | | P | | 42 ⁽¹⁾ | A | \$2.73 | 17,472 | D | |
| Common Stock | 10/12/2021 | | P | | 42 ⁽¹⁾ | A | \$2.71 | 17,514 | D | |
| Common Stock | 10/13/2021 | | P | | 42 ⁽¹⁾ | A | \$2.71 | 17,556 | D | |
| Common Stock | 10/14/2021 | | P | | 42 ⁽¹⁾ | A | \$2.81 | 17,598 | D | |
| Common Stock | 10/15/2021 | | P | | 42 ⁽¹⁾ | A | \$2.76 | 17,640 | D | |
| Common Stock | 10/18/2021 | | P | | 42 ⁽¹⁾ | A | \$2.75 | 17,682 | D | |
| Common Stock | 10/19/2021 | | P | | 42 ⁽¹⁾ | A | \$2.76 | 17,724 | D | |
| Common Stock | 10/20/2021 | | P | | 42 ⁽¹⁾ | A | \$2.63 | 17,766 | D | |
| Common Stock | 10/21/2021 | | P | | 42 ⁽¹⁾ | A | \$2.65 | 17,808 | D | |
| Common Stock | 10/22/2021 | | P | | 42 ⁽¹⁾ | A | \$2.66 | 17,850 | D | |
| Common Stock | 10/25/2021 | | P | | 42 ⁽¹⁾ | A | \$2.64 | 17,892 | D | |
| Common Stock | 10/26/2021 | | P | | 42 ⁽¹⁾ | A | \$2.64 | 17,934 | D | |
| Common Stock | 10/27/2021 | | P | | 42 ⁽¹⁾ | A | \$2.61 | 17,976 | D | |
| Common Stock | 10/28/2021 | | P | | 42 ⁽¹⁾ | A | \$2.61 | 18,018 | D | |
| Common Stock | 10/29/2021 | | P | | 42 ⁽¹⁾ | A | \$2.72 | 18,060 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----|---|--|--|---|--|
| | | | | Code | V | | (A) | (D) | | | | | |

Explanation of Responses:

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.

Remarks:

James Jones by /s/ John
Hamm as attorney-in-fact

11/05/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.